ATE264837T1 - N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate - Google Patents

N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate

Info

Publication number
ATE264837T1
ATE264837T1 AT00971396T AT00971396T ATE264837T1 AT E264837 T1 ATE264837 T1 AT E264837T1 AT 00971396 T AT00971396 T AT 00971396T AT 00971396 T AT00971396 T AT 00971396T AT E264837 T1 ATE264837 T1 AT E264837T1
Authority
AT
Austria
Prior art keywords
guanidinalkylamides
production
pharmaceutical preparations
preparations containing
pharmaceutical
Prior art date
Application number
AT00971396T
Other languages
German (de)
English (en)
Inventor
Otmar Klingler
Gerhard Zoller
Elisabeth Defossa
Fahad Al-Obeidi
Armin Walser
James Ostrem
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE264837T1 publication Critical patent/ATE264837T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
AT00971396T 1999-10-30 2000-10-21 N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate ATE264837T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99121623A EP1095933A1 (en) 1999-10-30 1999-10-30 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
PCT/EP2000/010395 WO2001032611A1 (en) 1999-10-30 2000-10-21 N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them

Publications (1)

Publication Number Publication Date
ATE264837T1 true ATE264837T1 (de) 2004-05-15

Family

ID=8239305

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00971396T ATE264837T1 (de) 1999-10-30 2000-10-21 N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate

Country Status (31)

Country Link
US (2) US6472562B1 (enExample)
EP (2) EP1095933A1 (enExample)
JP (1) JP4658430B2 (enExample)
KR (1) KR100981593B1 (enExample)
CN (1) CN1249026C (enExample)
AR (1) AR026257A1 (enExample)
AT (1) ATE264837T1 (enExample)
AU (1) AU776797B2 (enExample)
BR (1) BR0015186A (enExample)
CA (1) CA2389412C (enExample)
CZ (1) CZ301855B6 (enExample)
DE (1) DE60010113T2 (enExample)
DK (1) DK1228039T3 (enExample)
EE (1) EE05168B1 (enExample)
ES (1) ES2220553T3 (enExample)
HR (1) HRP20020372B1 (enExample)
HU (1) HUP0203627A3 (enExample)
IL (2) IL149209A0 (enExample)
ME (1) MEP54708A (enExample)
MX (1) MXPA02003805A (enExample)
NO (1) NO328016B1 (enExample)
NZ (1) NZ518607A (enExample)
PL (1) PL203859B1 (enExample)
PT (1) PT1228039E (enExample)
RS (1) RS50471B (enExample)
RU (1) RU2253651C2 (enExample)
SI (1) SI1228039T1 (enExample)
SK (1) SK286856B6 (enExample)
TR (1) TR200201181T2 (enExample)
WO (1) WO2001032611A1 (enExample)
ZA (1) ZA200203294B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1644401E (pt) * 2003-07-04 2011-06-06 Lonza Ag Acesso melhorado para síntese em fase suportada
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
RU2377990C1 (ru) * 2008-07-23 2010-01-10 Федеральное Государственное Образовательное Учреждение Высшего Профессионального Образования "Южный Федеральный Университет" Антитромботическое средство, влияющее на регуляцию функциональной активности тромбоцитов
CA2743496C (en) 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
PL3604510T3 (pl) 2009-03-30 2025-07-28 Alexion Pharmaceuticals, Inc. Antidota na inhibitory czynnika xa i sposoby ich stosowania
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
CN110357800B (zh) * 2018-04-09 2022-07-26 青岛海生洋润生物科技有限公司 脯氨酸衍生物及其在制备治疗心脑血管疾病药物中的应用
CN121221582A (zh) * 2021-05-10 2025-12-30 中国海洋大学 一种苯酰胍衍生物在用于制备预防和治疗神经系统疾病或心血管系统疾病的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU206372B (en) * 1990-09-03 1992-10-28 Richter Gedeon Vegyeszet Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994017635A1 (en) 1993-01-20 1994-08-04 Peter John Alexandrovics A line monitoring system
NZ263084A (en) * 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
ZA953361B (en) 1994-04-26 1996-01-12 Selectide Corp Factor Xa inhibitors
NZ296210A (en) * 1994-12-02 1998-05-27 Yamanouchi Pharma Co Ltd Amidinonaphthyl derivatives to inhibit activated blood coagulation factor x
US6342504B1 (en) * 1994-12-13 2002-01-29 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
EP1020434A4 (en) * 1997-08-27 2000-11-15 Kissei Pharmaceutical 3-AMIDINOANILINE DERIVATIVES, INHIBITORS OF THE ACTIVATED BLOOD COINTENANCE FACTOR X AND INTERMEDIATE PRODUCTS FOR PRODUCING BOTH
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
BR9814340B1 (pt) 1997-12-24 2010-07-13 compostos derivados de indol, processo para a preparação dos mesmo e composição farmacêutica.
WO1999037643A1 (en) * 1998-01-26 1999-07-29 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
US6348482B1 (en) * 1999-05-05 2002-02-19 Merck & Co., Inc. Catechols as antimicrobial agents

Also Published As

Publication number Publication date
PL354808A1 (en) 2004-02-23
EP1228039A1 (en) 2002-08-07
EE200200199A (et) 2003-06-16
CA2389412C (en) 2009-12-01
AU1026501A (en) 2001-05-14
CZ301855B6 (cs) 2010-07-14
PT1228039E (pt) 2004-09-30
ZA200203294B (en) 2003-01-29
CA2389412A1 (en) 2001-05-10
RU2002114041A (ru) 2004-01-20
CZ20021489A3 (cs) 2002-07-17
WO2001032611A1 (en) 2001-05-10
DE60010113T2 (de) 2005-05-04
NZ518607A (en) 2003-10-31
HRP20020372A2 (en) 2004-08-31
AU776797B2 (en) 2004-09-23
TR200201181T2 (tr) 2002-09-23
US6664393B2 (en) 2003-12-16
US20030162967A1 (en) 2003-08-28
HRP20020372B1 (hr) 2011-01-31
NO20022022L (no) 2002-04-29
MEP54708A (en) 2011-05-10
AR026257A1 (es) 2003-02-05
CN1249026C (zh) 2006-04-05
YU29702A (sh) 2005-06-10
SI1228039T1 (en) 2004-10-31
PL203859B1 (pl) 2009-11-30
DK1228039T3 (da) 2004-08-16
IL149209A (en) 2007-06-03
IL149209A0 (en) 2002-11-10
RS50471B (sr) 2010-03-02
DE60010113D1 (de) 2004-05-27
KR20020047310A (ko) 2002-06-21
HUP0203627A2 (hu) 2003-03-28
ES2220553T3 (es) 2004-12-16
NO20022022D0 (no) 2002-04-29
US6472562B1 (en) 2002-10-29
MXPA02003805A (es) 2004-10-15
HUP0203627A3 (en) 2004-12-28
SK5782002A3 (en) 2002-10-08
EP1228039B1 (en) 2004-04-21
RU2253651C2 (ru) 2005-06-10
NO328016B1 (no) 2009-11-09
JP4658430B2 (ja) 2011-03-23
BR0015186A (pt) 2002-07-23
EP1095933A1 (en) 2001-05-02
EE05168B1 (et) 2009-06-15
KR100981593B1 (ko) 2010-09-13
CN1387508A (zh) 2002-12-25
SK286856B6 (sk) 2009-06-05
HK1050673A1 (en) 2003-07-04
JP2003513066A (ja) 2003-04-08

Similar Documents

Publication Publication Date Title
ATE248811T1 (de) Indanylsubstituierte benzolcarbonamide, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltende pharmazeutische zubereitungen
ATE252562T1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69811735D1 (de) Heterocyclische verbindungen zur hemmung der magensäureproduktion, verfahren zu ihrer herstellung und pharmazeutische zubereitungen davon
ATE215951T1 (de) Tetracyclische campothecineanalogue, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen
DE69723571D1 (de) Methyliden-malonat nanopartikel, verfahren zu deren herstellung, und diese enthaltende pharmazeutische praeparate
DE50013167D1 (de) 2'-substituierte 1,1'-biphenyl-2-carboxamide, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltende pharmazeutische zubereitungen
ATE302754T1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69902535D1 (de) Phenoxypropanolamin-derivate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen zusammensetzungen
ATE234291T1 (de) Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
ATE279392T1 (de) Indol-verbindungen, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre medizinische anwendung
DE69909209D1 (de) Pyrimidinon-derivate, diese verbindungen enthaltenden pharmazeutische zubereitungen und verfharen zu ihrer herstellung
ATE294175T1 (de) 4-sulfonamid-piperidin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
DE3484925D1 (de) Pyrazolochinoline, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen.
DE60010113D1 (de) N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate
ATE370951T1 (de) Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
ATE305471T1 (de) Naphthyridine derivate, verfahren zu ihrer herstellung, deren anwendung und sie enthaltende pharmazeutische zusammensetzungen
ATE337317T1 (de) Imidazopyrin-derivate, verfahren zu ihrer herstellung and sie enthaltende pharmazeutische zusamensetzungen
DE60013463D1 (de) Pharmazeutische produkte und verfahren zu deren herstellung
ATE241637T1 (de) Pentasaccharide, verfahren zu ihrer herstellung und pharmazeutische zubereitungen die sie enthalten
ATE354356T1 (de) Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
DE60123292D1 (de) Uht-milchkonzentratspackung und verfahren zu ihrer herstellung
ATE260270T1 (de) 3-amido-chromanylsulfonyl(thio)harnstoffe, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische präparate
DE60003662D1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATE250051T1 (de) Sulfonamid-substituierte benzopyranderivate, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltende pharmazeutische zubereitungen
DE60013418D1 (de) Morpholinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1228039

Country of ref document: EP